<DOC>
	<DOCNO>NCT02548949</DOCNO>
	<brief_summary>On 6 Feb 2014 , Pristiq approve treatment Major Depressive Disorder ( MDD ) Korea . In accordance Standards Re-examination New Drug , require conduct PMS 600 patient 5 Feb 2020 . Post marketing surveillance require determine problem question associate Pristiq marketing , regard follow clause condition general clinical practice . Therefore , study , effectiveness safety pristiq observe .</brief_summary>
	<brief_title>Korean Post Marketing Surveillance Observe Effectiveness Safety PRISTIQ</brief_title>
	<detailed_description>The objective study determine problem question associate Pristiq marketing , regard follow clause condition general clinical practice , compliance regulation `` Re-examination guideline new drug ( Ministry Food Drug Safety Notification 2013-251 , 2013.12.20 ) '' . 1 . Serious adverse event/adverse drug reaction 2 . Unexpected adverse event/adverse drug reaction reflect approved drug label . 3 . Known adverse drug reaction 4 . Non-serious adverse drug reaction 5 . Other safety effectiveness information</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>1 . Adults 19 year age old , receive least one dose PRISTIQ® treatment Major depressive disorder ( MDD ) . 2 . Patients receive first time sign 'data privacy statement ' Patients PRISTIQ® contraindicate per local labeling ; 1 . Hypersensitivity desvenlafaxine succinate , venlafaxine hydrochloride excipients PRISTIQ® formulation . 2 . Serotonin syndrome MAOIs : Do use MAOIs intend treat psychiatric disorder PRISTIQ® Do use PRISTIQ® within 14 day stop MAOI intend treat psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>